RxDoctor Payments Data

Joseph Freeman

Family Medicine · Covington, TNNPI 1194179101

Payments from drug & device makers

$900in general payments, 2019–2025

Across 39 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$380
  • Heron Therapeutics, Inc.$122
  • Novo Nordisk$95
  • Lilly USA, LLC$72
  • Exact Sciences$66
  • Otsuka America Pharmaceutical, Inc.$33
  • plus $133 from 7 others

What the payments were for

  • Food & beverage$900100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$900 in reported general payments places this provider in the 55th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$170,962
Medicare patients
393
Services billed
6,502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide190$220,627
JardianceEmpagliflozin145$116,974
OzempicSemaglutide102$108,820
Trelegy ElliptaFluticasone/Umeclidin/Vilanter135$97,053
EliquisApixaban106$87,690
FarxigaDapagliflozin Propanediol40$42,090
LinzessLinaclotide41$35,400
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$29,072
TrulicityDulaglutide26$27,813
MyrbetriqMirabegron32$21,211
XareltoRivaroxaban20$20,177
VraylarCariprazine Hcl11$14,760
JanuviaSitagliptin Phosphate13$11,511
Lantus SolostarInsulin Glargine,hum.Rec.Anlog72$9,171
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,022

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$72$248,440216 claims
Boehringer IngelheimJardiance, Spiriva Respimat$18$123,858158 claims
Novo NordiskOzempic$95$108,820102 claims
PfizerEliquis$21$87,690106 claims
AstraZenecaFarxiga, Breztri Aerosphere$380$71,16278 claims
MerckJanuvia, Dulera$15$15,55125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Covington

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →